harm reduction | CARLAT PUBLISHING

Expert Q&A

The State of Opioids on the Street

May 29, 2023

Daniel Ciccarone, MD, MPH.

Justine Miner Professor of Addiction Medicine at the University of California San Francisco.

Dr. Ciccarone is a member of the scientific advisory board for Celero Systems. Relevant financial relationships listed for the author have been mitigated.

Dr. Ciccarone sheds light on the current chaotic and perilous situation surrounding illicit opioids found on the streets.

Clinical Update

Fentanyl Testing: An Emerging Harm Reduction Strategy

May 29, 2023

Noah Capurso, MD and Alyssa Falleni, PharmD

Alyssa Falleni, PharmD. CT Health Education and Research in SUD and Related Harms (CHERISH) Fellow; VA Connecticut Healthcare System, Orange, CT.

Noah Capurso, MD, MHS. Assistant Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief of The Carlat Addiction Treatment Report.

Dr. Falleni and Dr. Capurso have no financial relationships with companies related to this material.

Discover the lifesaving potential of fentanyl test strips (FTS). As fentanyl infiltrates illicit drug markets, FTS offer an essential harm reduction strategy. We’ll explore the technology behind FTS, how to obtain and use them, discuss their legality, and examine their role in preventing opioid overdose deaths.

Expert Q&A

Substance Use Disorders in Older Adults: A Growing Concern

May 11, 2023

Olivera J. Bogunovic, MD

Olivera J. Bogunovic, MD.

Medical director of ambulatory services in the Division of Alcohol, Drugs, and Addiction at McLean Hospital, Belmont, MA; assistant professor of psychiatry, Harvard Medical School, Boston, MA.

Dr. Bogunovic has no financial relationships with companies related to this material.

Older adults with substance use disorders present to clinicians in various stages of change. Dr. Bogunovic discusses brief clinical interventions including motivational interviewing and how to approach harm reduction.

Supervised Drug Consumption Sites

November 14, 2022

Noah Capurso, MD, MHS and Christopher Clayton, MD, EdM

Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

Supervised Drug Consumption

July 1, 2022

Christopher Clayton, MD, EdM and Deepti Anbarasan, MD.

Christopher L. Clayton, MD, EdM. PGY-4 psychiatry resident, NYU Gorssman School of Medicine, New York, NY.

Deepti Anbarasan, MD. Associate Professor in Psychiatry and Neurology, New York University, New York, NY.

Dr. Clayton and Dr. Anbarasan, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Supervised Consumption Sites are clinical settings where patients can use drugs in as safe a manner as possible. Clients are supplied with sterile equipment and the clinics are staffed by medical professionals who can respond in the case of an overdose. Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

Supervised Drug Consumption

July 1, 2022

Deepti Anbarasan, MD and Christopher Clayton, MD, EdM

Christopher L. Clayton, MD, EdM. PGY-4 psychiatry resident, NYU Gorssman School of Medicine, New York, NY. Deepti Anbarasan, MD. Associate Professor in Psychiatry and Neurology, New York University, New York, NY.

Dr. Clayton and Dr. Anbarasan, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Supervised Consumption Sites are clinical settings where patients can use drugs in as safe a manner as possible. Clients are supplied with sterile equipment and the clinics are staffed by medical professionals who can respond in the case of an overdose. Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.